JP5290185B2 - 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法 - Google Patents

置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法 Download PDF

Info

Publication number
JP5290185B2
JP5290185B2 JP2009536493A JP2009536493A JP5290185B2 JP 5290185 B2 JP5290185 B2 JP 5290185B2 JP 2009536493 A JP2009536493 A JP 2009536493A JP 2009536493 A JP2009536493 A JP 2009536493A JP 5290185 B2 JP5290185 B2 JP 5290185B2
Authority
JP
Japan
Prior art keywords
isobutyl
dimethoxy
pyrido
hexahydro
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009536493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509366A5 (enExample
JP2010509366A (ja
Inventor
カイル ダブリュー． ガノ，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5290185(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2010509366A publication Critical patent/JP2010509366A/ja
Publication of JP2010509366A5 publication Critical patent/JP2010509366A5/ja
Application granted granted Critical
Publication of JP5290185B2 publication Critical patent/JP5290185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009536493A 2006-11-08 2007-11-08 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法 Active JP5290185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86494406P 2006-11-08 2006-11-08
US60/864,944 2006-11-08
PCT/US2007/084176 WO2008058261A1 (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Publications (3)

Publication Number Publication Date
JP2010509366A JP2010509366A (ja) 2010-03-25
JP2010509366A5 JP2010509366A5 (enExample) 2011-11-24
JP5290185B2 true JP5290185B2 (ja) 2013-09-18

Family

ID=39110526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536493A Active JP5290185B2 (ja) 2006-11-08 2007-11-08 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法

Country Status (16)

Country Link
US (2) US8039627B2 (enExample)
EP (1) EP2081929B1 (enExample)
JP (1) JP5290185B2 (enExample)
KR (1) KR101500766B1 (enExample)
CN (1) CN101553487B (enExample)
AU (1) AU2007317242B2 (enExample)
BR (1) BRPI0718247B1 (enExample)
CA (1) CA2668689C (enExample)
DK (1) DK2081929T3 (enExample)
EA (1) EA018378B1 (enExample)
ES (1) ES2402220T3 (enExample)
IL (1) IL198250A0 (enExample)
MX (1) MX2009004910A (enExample)
PL (1) PL2081929T3 (enExample)
PT (1) PT2081929E (enExample)
WO (1) WO2008058261A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012000308A1 (zh) * 2010-06-29 2012-01-05 中国药科大学 丁苯那嗪的拆分方法
US8351329B2 (en) * 2010-09-14 2013-01-08 Cisco Technology, Inc. Universal load-balancing tunnel encapsulation
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
EP2897615A4 (en) 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US20160068526A1 (en) 2013-01-31 2016-03-10 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015048370A1 (en) * 2013-09-27 2015-04-02 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
EP3424504A1 (en) * 2013-12-03 2019-01-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015120317A1 (en) 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
KR20240011255A (ko) * 2014-05-06 2024-01-25 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
CN107438606B (zh) * 2015-02-06 2020-09-18 纽罗克里生物科学有限公司 [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法
WO2016144901A1 (en) 2015-03-06 2016-09-15 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
MX390795B (es) * 2015-06-23 2025-03-21 Neurocrine Biosciences Inc Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
WO2017060870A1 (en) 2015-10-09 2017-04-13 Hermann Russ Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
CN115304596A (zh) * 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
WO2017182916A1 (en) * 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
US10442800B2 (en) * 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
WO2018067945A1 (en) * 2016-10-06 2018-04-12 Assia Chemical Industries Ltd. Solid state forms of valbenazine
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
MY199695A (en) * 2017-01-27 2023-11-18 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2018153632A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
KR20230003308A (ko) 2017-03-15 2023-01-05 오스펙스 파마슈티칼스, 인코포레이티드 듀테트라베나진의 유사체, 이의 제조 및 용도
GB201705303D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
DK3684333T3 (da) 2017-09-21 2025-05-12 Neurocrine Biosciences Inc Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
RU2020114598A (ru) 2017-11-08 2021-12-09 Фореси Фармасьютикалс Ко., Лтд. Сложные эфиры дигидротетрабеназина
US11384077B2 (en) 2017-11-22 2022-07-12 Assia Chemical Industries Ltd. Solid state form of Valbenazine
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
CN110092785A (zh) * 2018-01-31 2019-08-06 广东东阳光药业有限公司 一种丁苯那嗪的动态拆分方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3065236A1 (en) 2018-12-27 2020-06-27 Apotex Inc. Novel crystalline form of valbenazine dibesylate
WO2020213014A1 (en) 2019-04-19 2020-10-22 Mylan Laboratories Limited An improved process for the preparation of valbenazine and its salts
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US12565495B2 (en) * 2019-08-12 2026-03-03 Luye Innomind Pharma Shijiazhuang Co., Ltd. VMAT2 inhibitor and preparation method therefor and application thereof
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN117736203A (zh) 2019-09-13 2024-03-22 纽罗克里生物科学有限公司 用于合成缬苯那嗪的方法
CN110698397A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 丁苯那嗪中间体及其合成方法、应用和合成用中间产物
AR125188A1 (es) 2021-03-22 2023-06-21 Neurocrine Biosciences Inc Inhibidores del vmat2 y métodos de uso
WO2022232060A1 (en) 2021-04-26 2022-11-03 Neurocrine Biosciences, Inc. Processes for the synthesis of valbenazine
EP4362944A1 (en) 2021-06-30 2024-05-08 Neurocrine Biosciences, Inc. Valbenazine for use in the add-on treatment of schizophrenia
MX2023014977A (es) 2021-06-30 2024-02-09 Neurocrine Biosciences Inc Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
IL315181A (en) 2022-03-07 2024-10-01 Neurocrine Biosciences Inc Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
CN119907800A (zh) 2022-09-21 2025-04-29 纽罗克里生物科学有限公司 六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025038938A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of huntington's chorea
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025199234A1 (en) 2024-03-20 2025-09-25 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) * 1958-07-15 Method for preparing same
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2852518A (en) * 1957-05-23 1958-09-16 Parke Davis & Co Di-substituted quinoline compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
EP2698170A1 (en) 2005-06-29 2014-02-19 The Trustees of Columbia University in the City of New York Use of DTBZ for imaging endocrine pancreas and beta cell mass in type 1 diabetes
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EP1855677B1 (en) 2005-08-06 2008-12-03 Cambridge Laboratories (Ireland) Limited 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto

Also Published As

Publication number Publication date
ES2402220T8 (es) 2021-12-23
EA018378B1 (ru) 2013-07-30
BRPI0718247B1 (pt) 2021-09-21
US8357697B2 (en) 2013-01-22
BRPI0718247A2 (pt) 2014-01-07
KR20090079257A (ko) 2009-07-21
AU2007317242B2 (en) 2013-08-01
US20120077839A1 (en) 2012-03-29
CN101553487A (zh) 2009-10-07
PL2081929T3 (pl) 2013-06-28
DK2081929T3 (da) 2013-04-15
EP2081929A1 (en) 2009-07-29
CN101553487B (zh) 2012-06-13
US8039627B2 (en) 2011-10-18
JP2010509366A (ja) 2010-03-25
KR101500766B9 (ko) 2024-09-25
CA2668689C (en) 2015-12-29
CA2668689A1 (en) 2008-05-15
WO2008058261A1 (en) 2008-05-15
EP2081929B1 (en) 2013-01-09
ES2402220T3 (es) 2013-04-29
KR101500766B1 (ko) 2015-03-16
EA200970461A1 (ru) 2009-12-30
AU2007317242A1 (en) 2008-05-15
IL198250A0 (en) 2009-12-24
MX2009004910A (es) 2009-07-24
PT2081929E (pt) 2013-04-15
US20080167337A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
JP5290185B2 (ja) 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
JP3356726B2 (ja) ５ＨＴ１Ａリガンドとしてのピロロ［１，２−ａ］ピラジン誘導体
US10604502B2 (en) Substituted 5-cyanoindole compounds and uses thereof
US11390623B2 (en) 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA3163933A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EA021765B1 (ru) Производные хиназолиндиона, их получение и их различные терапевтические применения
WO2018023009A1 (en) Deuterated lurasidone
IL317345A (en) Tricyclic substances and pharmaceutical preparations containing them
HK40000945B (en) 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
HK1262295A1 (en) 6,7-dihydro-5h-pyrazolo[5，1-b][1,3]oxazine-2-carboxamide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130605

R150 Certificate of patent or registration of utility model

Ref document number: 5290185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250